NEW YORK, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Intra-Cellular Therapies, Inc. ("Intra-Cellular " or the “Company") (NASDAQ: ITCI). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/itci.
The investigation concerns whether Intra-Cellular and certain of its officers and/or directors have violated federal securities laws.
On December 18, 2018, Intra-Cellular Therapies issued a press release announcing that “an independent data monitoring committee (DMC) has completed a pre-specified interim analysis of the Company’s ongoing clinical trial with low-dose lumateperone (9 mg ITI-007) for the treatment of agitation in patients with probable Alzheimer's disease (Study 201).” Intra-Cellular Therapies stated that “[t]he DMC concluded that Study 201 is not likely to meet its primary endpoint upon completion and therefore recommended the study should be stopped for futility. As a result of this recommendation, the Company has determined to discontinue Study 201.” Following this announcement, Intra-Cellular Therapies’ stock price fell sharply during intraday trading on December 18, 2018.
If you are aware of any facts relating to this investigation, or purchased Intra-Cellular shares, you can assist this investigation by visiting the firm’s site: bgandg.com/itci. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com